Table 3.

Evaluation and Outcomes of Patients With First-Dose Messenger RNA Coronavirus Disease 2019 Vaccine Reactions

Evaluation and outcomes	Tolerateda second vaccine dose, n = 36	Symptomsa with second vaccine dose, n = 7	Deferred second vaccine dose, n = 12	P valueb
Skin test performedc
PEG (%)
MiraLAX (PEG3350)	36 (100)	7 (100)	12 (100)	.99
Methylprednisolone acetate	18 (50)	4 (57.1)	10 (83.3)	.73
Methylprednisolone sodium	16 (44.4)	5 (71.4)	8 (66.7)	.24
Polysorbate 80 (%)
Triamcinolone acetonide	10 (27.8)	3 (42.9)	7 (58.3)	.66
Prevnar-13	7 (19.4)	3 (42.9)	3 (25.0)	.32
Polysorbate 20 (%)
Flublok	0 (0)	0 (0)	2 (16.7)	.99
Havrix	6 (16.7)	2 (28.6)	3 (25.0)	.60
Polysorbate 20 compound	9 (25.0)	3 (42.9)	5 (41.7)	.38
Pfizer-BioNTech vaccine (%)	6 (16.7)	1 (14.3)	1 (8.3)	.86
Moderna vaccine (%)	1 (2.8)	1 (14.3)	1 (8.3)	.30
Average days from index reaction to skin test (SD)	28.9 (18.2)	24.4 (11.5)	49.2 (27.1)	.12
Positive skin test results (total, %)	2 (5.6)	1 (14.3)	1 (8.3)	.42
PEG	0 (0)	0 (0)	0 (0)
Polysorbate	2 (5.6)d	1 (14.3)e	1 (8.3)f
Vaccine	0 (0)	(0)	0 (0)
Vaccine received (%)
Pfizer-BioNTech	26 (72.2)	5 (71.4)	N/A	.99
Moderna	10 (27.8)	2 (28.6)	N/A	.99
Janssen	0 (0)	0 (0)	N/A	.99
Average days between first and second vaccine doses (SD)	39.7 (18.4)	35.3 (13.3)	N/A	.55

Abbreviations: COVID-19, coronavirus disease 2019; ID, intradermal; F, flare; IM, intramuscular; mRNA, messenger RNA; N/A, not available; PEG, polyethylene glycol; W, wheal.

^aTolerance: No allergic symptoms experienced. In 7 patients who had allergic symptoms, none required epinephrine.

^bP values represent comparison between the “tolerated vaccine dose” group and “symptoms with vaccine dose” group.

^cSee Table 1 for concentrations used.

^dPatient 1: Triamcinolone acetonide 1:100 ID (5×5W, 15×10F). Patient 2: triamcinolone acetonide 1:1 ID (3×3W, 8×8F).

^eTriamcinolone acetonide 1:10 ID (4×3W, 15×10F).

^fFlublok: 1:100 ID (10×11W, 35×55F).